{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T11:48:37Z","timestamp":1711540117001},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"S6","license":[{"start":{"date-parts":[[1996,11,1]],"date-time":"1996-11-01T00:00:00Z","timestamp":846806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pflugers Arch."],"published-print":{"date-parts":[[1996,11]]},"DOI":"10.1007\/bf02346385","type":"journal-article","created":{"date-parts":[[2006,3,15]],"date-time":"2006-03-15T23:17:37Z","timestamp":1142464657000},"page":"R295-R296","source":"Crossref","is-referenced-by-count":7,"title":["3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome"],"prefix":"10.1007","volume":"431","author":[{"given":"J.","family":"Molg\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02346385_CR1","first-page":"87","volume":"34","author":"JD Cooke","year":"1994","unstructured":"Cooke JD, Hefter H, Brown SH, Touka KV, Freund HJ (1994) Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy. Electromyogr clin Neurophysiol 34: 87\u201393","journal-title":"Electromyogr clin Neurophysiol"},{"key":"BF02346385_CR2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1212\/WNL.26.10.944","volume":"26","author":"M Cherington","year":"1976","unstructured":"Cherington M (1976) Guanidine and germine in Eaton-Lambert syndrome. Neurology 26: 944\u2013966","journal-title":"Neurology"},{"key":"BF02346385_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1113\/jphysiol.1980.sp013145","volume":"299","author":"SG Cull-Candy","year":"1980","unstructured":"Cull-Candy SG, Miledi R, Trautmann A, Uchitel OD (1980) On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates. J Physiol (Lond) 299: 621\u2013638","journal-title":"J Physiol (Lond)"},{"key":"BF02346385_CR4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1749-6632.1991.tb36496.x","volume":"635","author":"AG Engel","year":"1991","unstructured":"Engel AG (1991) Review of evidence for loss of motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci 635: 246\u2013258","journal-title":"Ann NY Acad Sci"},{"key":"BF02346385_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0404.1977.tb01417.x","volume":"56","author":"KG Henriksson","year":"1977","unstructured":"Henriksson KG, Nilsson O, Rosen I, Schiller HH (1977) Clinical neurophysiological and morphological findings in Eaton-Lambert syndrome. Acta Neurol Scand 56: 117\u2013140","journal-title":"Acta Neurol Scand"},{"key":"BF02346385_CR6","first-page":"776","volume":"148","author":"WJ Jost","year":"1992","unstructured":"Jost WJ, Mielke U, Forret-Kaminsky MC, Schmirigk K (1992) Traitement au long cours du syndrome de Lambert-Eaton par la 3,4-diaminopyridine. Rev Neurol (Paris) 148:776\u2013779","journal-title":"Rev Neurol (Paris)"},{"key":"BF02346385_CR7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/archneur.1975.00490500025001","volume":"32","author":"MA Kamesnskaya","year":"1975","unstructured":"Kamesnskaya MA, Elmqvist D, Thesleff S (1975) Guanidine and neuromuscular transmission. Arch Neurol 32: 505\u2013518","journal-title":"Arch Neurol"},{"key":"BF02346385_CR8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1126\/science.2447652","volume":"239","author":"YI Kim","year":"1988","unstructured":"Kim YI, Neher E (1988) IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels. Science 239: 405\u2013408","journal-title":"Science"},{"key":"BF02346385_CR9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ana.410250310","volume":"25","author":"B Lang","year":"1989","unstructured":"Lang B, Vincent A, Murray NMF, Newsom-Davis J (1989) Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity. Ann Neurol 25:265\u2013271","journal-title":"Ann Neurol"},{"key":"BF02346385_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.1971.tb30750.x","volume":"183","author":"EH Lambert","year":"1971","unstructured":"Lambert EH, Elmqvist D (1971) Quantal components of end-plate potentials in the myasthenic syndrome. Ann New York Acad Sci 183: 183\u2013199","journal-title":"Ann New York Acad Sci"},{"key":"BF02346385_CR11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0006-8993(84)90875-8","volume":"304","author":"M Lemeignan","year":"1984","unstructured":"Lemeignan M, Millart H, Lamiable D, Molgo J, Lechat P (1984) Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res 304: 166\u2013169","journal-title":"Brain Res"},{"key":"BF02346385_CR12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp.40.11.1109","volume":"40","author":"H Lundh","year":"1977","unstructured":"Lundh H, Nilsson O, Rosen I (1977) 4-aminopyridine: a new drug test in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 40: 1109\u20131112","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF02346385_CR13","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp.46.7.684","volume":"46","author":"H Lundh","year":"1983","unstructured":"Lundh H, Nilsson O, Rosen I, Johansson S (1983) Novel drug of choice in Lambert-Eaton syndrome. J Neurol Neurosurg Psychiatry 46: 684\u2013687","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF02346385_CR14","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1212\/WNL.34.10.1324","volume":"34","author":"H Lundh","year":"1984","unstructured":"Lundh H, Nilsson O, Rosen I (1984) Treatment of Lambert-Eaton muastheme syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 34: 1324\u20131330.","journal-title":"Neurology"},{"key":"BF02346385_CR15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.1993.tb04205.x","volume":"88","author":"H Lundh","year":"1993","unstructured":"Lundh H, Nilsson O, Rosen I, Johansson S (1993) Practical aspects of 3,4- diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 88: 136\u2013140","journal-title":"Acta Neurol Scand"},{"key":"BF02346385_CR16","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA (1989) 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321: 1567\u20131571","journal-title":"N Engl J Med"},{"key":"BF02346385_CR17","first-page":"1637","volume":"281","author":"J Molgo","year":"1975","unstructured":"Molgo J, Lemeignan M, Lechat P (1975) Modifications de la lib\u00e9ration du transmetteur \u00e0 la jonction neuromusculaire de Grenouille sous l'action de l'amino-4-pyridine. C R Acad Sci (Paris) Ser D 281: 1637\u20131639","journal-title":"C R Acad Sci (Paris) Ser D"},{"key":"BF02346385_CR18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-2999(80)90378-7","volume":"61","author":"J Molgo","year":"1980","unstructured":"Molgo J, Lundh H, Thesleff S (1980) Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effects of pH changes. Eur J Pharmacol 61: 25\u201334","journal-title":"Eur J Pharmacol"},{"key":"BF02346385_CR19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0304-3940(88)90374-6","volume":"89","author":"J Molgo","year":"1988","unstructured":"Molgo J, Millart A (1988) The mode of action of guanidine on mouse motor nerve terminals. Neurosci Lett 89: 161\u2013164","journal-title":"Neurosci Lett"},{"key":"BF02346385_CR20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.31.3.265","volume":"31","author":"NMF Murray","year":"1981","unstructured":"Murray NMF, Newsom-Davis J (1981) Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31: 265\u2013271","journal-title":"Neurology"},{"key":"BF02346385_CR21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O'Neill","year":"1988","unstructured":"O'Neill JH, Murray NMF, Newsom-Davis J (1988) The Lambert-Eaton myasthenic sundrome: a review of 50 cases. Brain 111: 577\u2013596","journal-title":"Brain"},{"key":"BF02346385_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-2008-1041067","volume":"14","author":"DB Sanders","year":"1994","unstructured":"Sanders DB (1994) Lambert-Eaton myasthenic syndrome: pathogenesis and treatment. Sem Neurol 14: 111\u2013117","journal-title":"Sem Neurol"},{"key":"BF02346385_CR23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1749-6632.1993.tb22949.x","volume":"681","author":"DB Sanders","year":"1993","unstructured":"Sanders DB, Howard JF, Massey JM (1993) 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis. Ann NY Acad Sci 681: 588\u2013590 22.","journal-title":"Ann NY Acad Sci"},{"key":"BF02346385_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1113\/jphysiol.1995.sp020865","volume":"487","author":"DO Smith","year":"1995","unstructured":"Smith DO, Conklin MW, Jensen PJ, Atchison D (1995) Decreased calcium current in motor nerve terminals of mice with Lambert-Eaton myasthenic syndrome. J Physiol (London) 487: 115\u2013123","journal-title":"J Physiol (London)"},{"key":"BF02346385_CR25","first-page":"496","volume":"12","author":"A Vincent","year":"1989","unstructured":"Vincent A, Lang B, Newsom-Davis J (1989) Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. TINS 12: 496\u2013502","journal-title":"TINS"}],"container-title":["Pfl\u00fcgers Archiv European Journal of Physiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02346385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02346385\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02346385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T06:14:05Z","timestamp":1558073645000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02346385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,11]]},"references-count":25,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[1996,11]]}},"alternative-id":["BF02346385"],"URL":"https:\/\/doi.org\/10.1007\/bf02346385","relation":{},"ISSN":["0031-6768","1432-2013"],"issn-type":[{"value":"0031-6768","type":"print"},{"value":"1432-2013","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,11]]}}}